Cargando…
Whole genome amplification of cell-free DNA enables detection of circulating tumor DNA mutations from fingerstick capillary blood
The ability to measure mutations in plasma cell-free DNA (cfDNA) has the potential to revolutionize cancer surveillance and treatment by enabling longitudinal monitoring not possible with solid tumor biopsies. However, obtaining sufficient quantities of cfDNA remains a challenge for assay developmen...
Autores principales: | Gyanchandani, Rekha, Kvam, Erik, Heller, Ryan, Finehout, Erin, Smith, Nicholas, Kota, Karthik, Nelson, John R., Griffin, Weston, Puhalla, Shannon, Brufsky, Adam M., Davidson, Nancy E., Lee, Adrian V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6251935/ https://www.ncbi.nlm.nih.gov/pubmed/30470782 http://dx.doi.org/10.1038/s41598-018-35470-9 |
Ejemplares similares
-
Detection of ESR1 mutations in circulating cell-free DNA from patients with metastatic breast cancer treated with palbociclib and letrozole
por: Gyanchandani, Rekha, et al.
Publicado: (2016) -
Sustained, Long-Term Maintenance of Remission with Single-Agent Veliparib in Recurrent Triple-Negative Breast Cancer
por: Kota, Karthik, et al.
Publicado: (2017) -
Targeted mutation detection in breast cancer using MammaSeq™
por: Smith, Nicholas G., et al.
Publicado: (2019) -
Ixabepilone: a new chemotherapeutic option for refractory metastatic breast cancer
por: Puhalla, Shannon, et al.
Publicado: (2008) -
Estradiol as a Targeted, Late-Line Therapy in Metastatic Breast Cancer with Estrogen Receptor Amplification
por: Kota, Karthik, et al.
Publicado: (2017)